PFSA PFSA
Company Profile ↓Company Overview
PFSA (PFSA) is a publicly traded company listed on with a market capitalization of $1.16M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 134.4%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 149.9%.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -99.92% |
| 6 Months: | -99.45% |
| 3 Months: | -92.76% |
| 1 Month: | -66.52% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)24.54 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 134.4%.
- Healthy ROCE of 149.9%.
CONS
- Trading 99.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 25 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 75.00K | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 1.42M | 967.08K | 21.71M | 3.57M | 4.01M |
| Operating Income | -338 | -241.60K | -217.53K | -404.43K | -443.72K | -314.71K | -290.10K | -470.84K | -253.13K | -1.10M | - | -1.42M | -967.08K | -21.71M | -3.57M | -4.01M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | -1.58M | -967.08K | -22.02M | -8.54M | -3.44M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 1.29M | 1.14M | - | 169.00K | 25.00K | 18.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | -2.72M | -8.19M | -22.19M | -8.57M | -3.46M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | 2.39K | - | - | - |
| Net Income | -338 | 3.71M | 1.21M | 1.76M | 440.89K | 852.39K | -367.35K | -2.07M | -2.41M | -2.50M | - | -2.72M | -8.20M | -22.19M | -8.57M | -3.46M |
| Diluted EPS | 0.00 | 0.15 | 0.05 | 0.05 | 0.02 | 0.14 | -0.06 | -0.14 | -0.07 | -1.29 | - | -6.21 | -18.75 | -52.50 | - | -2.05 |
| R&D Expense | - | - | - | - | - | - | - | - | - | 411.00K | - | 434.00K | - | 722.00K | - | 1.15M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 9.44M | 6.07M | 4.50M | 27.71M |
| Operating Income | - | -9.44M | -6.07M | -4.50M | -27.71M |
| EBITDA | - | -13.22M | -6.00M | -4.81M | -33.30M |
| Interest Expense | - | 6.27M | 4.28M | 4.42M | 2.52M |
| Pretax Income | - | -20.22M | -10.28M | -9.23M | -35.82M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -20.22M | -10.28M | -9.23M | -35.82M |
| Diluted EPS | - | -46.24 | -23.52 | -21.11 | -107.01 |
| R&D Expense | - | - | - | 1.61M | 2.80M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.03M | 1.89M | 3.07M | 3.77M |
| Current Assets | - | 160.00K | 333.00K | 260.00K | 3.76M |
| Cash & Equivalents | - | 78.00K | 142.00K | 191.00K | 1.78M |
| Inventory | - | - | - | - | - |
| Receivables | 38.00K | 0 | - | - | - |
| Total Liabilities | - | 100.80M | 111.89M | 122.28M | 30.43M |
| Current Liabilities | - | 35.65M | 46.74M | 57.13M | 22.26M |
| Long Term Debt | 1.19M | - | - | - | 7.88M |
| Total Debt | - | 31.03M | 40.40M | 48.21M | 14.81M |
| Total Equity | - | -99.77M | -110.00M | -119.20M | -26.66M |
| Shares Outstanding | - | 437.19K | 437.19K | 1.23M | 1.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -7.70M | -4.40M | -2.07M | -16.25M |
| Investing Cash Flow | - | - | -2.00K | 0 | -2.01M |
| Financing Cash Flow | - | 6.92M | 4.47M | 2.12M | 19.84M |
| Capital Expenditure | - | - | -2.00K | - | -8.00K |
| Free Cash Flow | - | -7.70M | -4.40M | -2.07M | -16.26M |
| Net Change in Cash | - | -778.00K | 64.00K | 49.00K | 1.59M |
| Share Buybacks | - | - | 184.85M | 3.25M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 20.3% | 9.3% | 7.7% | 134.4% |
| ROCE % | - | 27.3% | 13.5% | 8.3% | 149.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PFSA
Profusa vies for potential G3 Vision Labs acquisition
If the acquisition goes ahead, Profusa will add several routine chemistry, toxicology and pathology diagnostic offerings to its portfolio.
Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs
BERKELEY, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of an Option Agreement (the “Agreement”) which provides Pro…
Profusa Signs Term Sheet for Diagnostics Acquisition and Announces Leadership Changes
Profusa (NASDAQ:PFSA) has signed a non-binding term sheet to acquire a commercial-stage diagnostics company with estimated 2025 net revenue of approximately $111 million, while also reshaping its executive leadership as it pivots toward a d…
Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company
BERKELEY, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of a non-binding term sheet with a privately held, commerci…
This Biotech Stock Crashed 28% Today After Announcing Second Reverse Share Split This Year
Profusa is set to implement a 1-for-25 reverse stock split on July 7.
Profusa Announces 1-for-25 Reverse Stock Split
BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring…
PFSA — Frequently Asked Questions
What is the current share price of PFSA?
As of 2026-08-05 17:25 PDT, PFSA trades at $0.94 on NASDAQ/NYSE. Its 52-week range is $0.94 to $1,115.62.
What is the market capitalisation of PFSA?
PFSA has a market capitalisation of $1.16M on NASDAQ/NYSE.
What is the P/E ratio of PFSA?
PFSA trades at a trailing price-to-earnings (P/E) ratio of -0.01. Its price-to-book (P/B) ratio is -0.04.
What is the return on equity (ROE) of PFSA?
PFSA has a return on equity (ROE) of 134.38%. Its return on capital employed (ROCE) is 149.90%.
Is PFSA a good stock to buy?
This page provides a data-driven analysis of PFSA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.